MW WeightWatchers' stock leaps as weight-loss-drug subscriptions boost revenue

By James Rogers

WW International, the company known as WeightWatchers, brought back its full-year outlook when it reported second-quarter results

WeightWatchers reported second-quarter results before market open Monday.

Shares of WW International Inc. were climbing Monday, after the company known as WeightWatchers reported better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity treatments.

WW, which emerged from bankruptcy on June 24, also brought back its full-year guidance when it reported its second-quarter results.

The stock $(WW)$ rallied 4.5% in morning trading. It has soared 47.8% from where it closed the on first day of trading after emerging from bankruptcy.

The New York City-based company gave "predecessor" results covering the period from March 30 to June 24 and "successor" results for the period from June 25 to June 30.

Predecessor net income was $1.191 billion, or $14.67 a share, although WW said that net income was impacted by the company's reorganization. Successor net income was $1.3 million, or 13 cents a share. For the prior year's quarter, or the three months ending June 29, 2024, net income was $23.3 million, or 29 cents a share.

WW's second-quarter combined revenue was $189.2 million, down 6.4% from $202.1 million in the same period last year. The one analyst who provided a revenue estimate to FactSet was expecting $178 million.

The company said that the revenue decline reflects ongoing headwinds in its behavioral business, although this was partially offset by 55% growth in revenue from its clinical business, driven by subscriptions to compounded GLP-1 semaglitude for weight loss.

When it emerged from bankruptcy in June, WW announced a new program to support women as they go through menopause, noting that this will harness GLP-1s.

In its statement WW said that, from May 22, its clinical business has been transitioning subscribers from compounded semaglutide to FDA-approved medications, in line with current FDA guidance.

Last year, WW announced the addition of the obesity treatments to its offerings. And last month, the company announced an expanded collaboration with Novo Nordisk A/S (NVO), which makes the FDA-approved weight-loss drug Wegovy.

After declining to provide a full-year outlook last quarter, investors seemed to appreciate that the company provided guidance this quarter. WW expects revenue between $685 million and $700 million, while the average estimate of two analysts surveyed by FactSet was for full-year sales of $700 million.

The company filed for bankruptcy in early May amid a mounting debt burden that offering GLP-1 weight-loss drugs couldn't cure. When it emerged from bankruptcy in June, WW said that it has "significantly enhanced" financial flexibility.

-James Rogers

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

August 11, 2025 09:50 ET (13:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.